Recent Updates
Recently added Catalysts
ALT

Altimmune to Present at Upcoming Investor and Scientific Conferences

Key Takeaway: GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following conferences: Piper Sandler 33rd Annual Virt

Full Press Release Details

GAITHERSBURG, Md., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will be presenting virtually at the following conferences:
Piper Sandler 33rd Annual Virtual Healthcare Conference
November 29-December 2, 2021
Webcast available now
5th Annual NASH Summit 2021
9:00 am Eastern Time
4th Annual Evercore ISI HealthCONx Conference
10:55 am Eastern Time
Presentation materials, including webcast links to the Piper Sandler and Evercore ISI presentations, will be accessible on the Events section of the Altimmune website.
Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Our pipeline includes next generation peptide therapeutics for obesity, NASH (pemvidutide), and chronic hepatitis B (HepTcell™). For more information, please visit www.altimmune.com.
Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter
Altimmune Investor & Media Contact:
Chief Financial Officer
Last updated: Nov 22, 2021